Background: The most widely used topical agents for the field-based treatment of multiple actinic keratoses (AKs) are 5-fluorouracil and imiquimod, but their comparative effectiveness has not been assessed in a real-world setting.
A ctinic keratoses (AKs) are keratinocytederived precancerous neoplasms that develop on chronically sun-exposed skin. 1 AKs arise in nearly 40 million Americans per year, [2] [3] [4] and treatment costs more than a billion dollars annually. 4 AKs can be treated with destructive therapies (cryotherapy, curettage, and chemical peels), topical chemotherapeutic agents (such as 5-fluorouracil , imiquimod [Imq] , diclofenac, tretinoin, and ingenol mebutate), and light-based treatments (lasers and photodynamic treatment). Treatment selection depends on a variety of factors, including patient characteristics and patient and provider preferences. Focally destructive treatments (lesion-directed) are suitable for treating a few discrete lesions. When a patient has numerous AKs in an anatomic unit, treatment of the broader field of disease (field treatment) with medications such 5-FU or Imq are used. In contrast to focally applied destructive modalities, field treatments can attack subclinical AKs, which may decrease the risk for future AKs and keratinocyte carcinomas (KCs) in the treated area.
There are no clearly established guidelines for the field treatment of AKs. There are several different types of field treatments, and there is considerable variation in how each field treatment is deployed. A Cochrane review on interventions for AKs concluded that ''more direct comparisons.are needed to determine the best therapeutic approach, '' 5 and a recent review on AKs noted that ''more head-to-head comparisons of alternative treatment strategies for AK are needed to determine the best treatment.'' 6 There are few real-world data comparing the effectiveness of 5-FU to Imq for field treatment of AKs. The translation of efficacy to effectiveness is especially urgent where disease prevalence is high and variations in cost and efficacy can have large impact.
MATERIALS AND METHODS
We performed a retrospective longitudinal cohort study of all Kaiser Permanente Northern California (KPNC) members with a diagnosed AK who filled prescriptions for 5-FU (n = 5062) or Imq (n = 638) in 2007. Cohort members were followed for subsequent AK diagnosis.
Study setting
KPNC is a prepaid, comprehensive, integrated care organization that serves 4 million members. KPNC's computerized record system provides a comprehensive record of members' demographic characteristics, pathology results, pharmacy use, and utilization benefits.
Study population
The To maximize uniformity in the cohort and minimize confounding by sun exposure, skin type, and other unmeasured potential risk factors, we limited eligibility to members who were prescribed a topical field-based treatment for their actinic damage. We did not include members who had AKs that were spot-treated or untreated so that we could a priori make AK severity as similar as possible across the treatment groups. Subjects were followed from the date of first dispensed AK treatment (cohort entry date) until the earliest of health plan disenrollment (defined as a membership gap [90 days), death, subsequent AK diagnosis, or end of the study period on December 31, 2012. Subjects were excluded if 5-FU or Imq was prescribed for any indication other than AK (such as warts or skin cancer) as determined by chart review, or if they had a history of any of the following ever recorded in the KPNC database: (1) ultraviolet light treatment; (2) infection with HIV; (3) chronic lymphocytic leukemia; (4) solid organ transplant; and (5) bone marrow transplant (Fig 1) . Patients with a history of ultraviolet light treatment were excluded because of the increased risk for skin cancer associated with these therapies. 7 Patients with a history of HIV infection, chronic lymphocytic leukemia, solid organ transplant, and bone marrow transplant were excluded because of the increased risk for skin cancer associated with immunosuppression.
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Exposure
Exposure was defined as pharmacy dispensation of 5-FU or Imq following an AK diagnosis in 2007. We found that compared with imiquimod, 5-fluorouracil was associated with reduced short-term risk for subsequent actinic keratoses, as identified by International Classification of Diseases, Ninth Revision, codes. These results can potentially inform selection of field-based treatments for actinic keratoses.
CAPSULE SUMMARY
Outcome
The outcome was time to subsequent AK diagnosis after cohort entry, defined as the first date after the start of follow-up when AK was recorded (ICD-9 code 702.0). Follow-up was right-censored by the earliest of health plan disenrollment, death, or end of the study period. We examined both short-term (within 2 years) and long-term (within 5 years) subsequent AK cumulative incidence. The Veterans Affairs Keratinocyte Carcinoma Chemoprevention trial, a randomized, double-blind, placebo-controlled trial of the long-term efficacy of 5-FU, found that a single course of 5-FU reduced AK counts and the need for spot treatments for longer than 2 years 12 ; we therefore selected 2 years as the first time point for follow-up. Given that we had up to 6 years of follow-up for cohort members, we chose 5 years for long-term follow-up.
Covariates
Information on potential confounders was obtained from KPNC's databases for patient demographics, including age (date of birth), sex (male, female), and race/ethnicity (white nonHispanic, white Hispanic, black, Asian, or Native American). Data on risk factors for AKs, including cigarette use (current former, never, or unknown), body mass index (#24.9 [normal], 25-29.9 [overweight], or $30 [obese]), comorbidities (Charlson score 0, 1, 2, or 31), health care utilization (average annual number of any health care provider emergency department or outpatient visits per year in the 2 years before baseline), surveillance measure (average annual number of dermatology visits per year in the 2 years before baseline), prior KC (yes or no within 5 years before baseline), prior AK (yes or no within 5 years before baseline), 5-FU treatment before cohort entry (yes or no), and photosensitizing medication use within 2 years before baseline, were also ascertained. Photosensitizing medications were categorized based on previously published work. 13 
Statistical analysis
The comparative effectiveness of 5-FU versus Imq was evaluated with an intention-to-treat propensity score (PS)-based analytic approach known as inverse probability weighting (IPW) estimation to adjust for potential confounding by baseline variables (ie, variables measured before the start of follow-up, including intensity of past surveillance and history of prior 5-FU treatment).
14 Differential noncompliance or surveillance between the agents was not expected because their directions for use, duration, and side effect profile are quite similar. 15 This rationale supported the intention-to-treat analytic approach comparing the outcomes between exposure groups defined by the type of medication dispensed rather than by the medication used and the duration of use.
The PS was estimated by logistic regression with main terms for all baseline variables. The short-and long-term cumulative risk differences were estimated by linear regression by using stabilized inverse probability (IP) weights calculated on the basis of these PS estimates. 16 Outcomes from patients with no new AK diagnosis and with less than 2 years of follow-up were treated as missing in the regression, and missingness was assumed to occur randomly. Conservative 95% confidence intervals (CIs) were derived on the basis of the robust variance estimator (sandwich estimator implemented in the SAS GENMOD procedure (SAS Institute Inc, Cary, NC) with the option repeated and an independence working correlation matrix). 17 We examined the distribution of the stabilized IPW weights to detect extreme weight values. The maximum IPW weight value did not warrant weight truncation. 16 Results from the aforementioned IPW estimation approach were compared with results from (1) crude (unadjusted) estimation of 
RESULTS
Of the 5700 patients in the cohort, 5062 were exposed to 5-FU and 638 were exposed to Imq. In the majority (n = 4946), a subsequent AK was diagnosed during follow-up. Of the 754 patients with no subsequent AK diagnosis, 289 were censored due to a membership gap of greater than 3 month, 100 were censored due to death, and 365 were followed through to the end of the study period. In total, 281 patients had no subsequent AK diagnosis before 2 years, and 441 had no subsequent AK diagnosis before 5 years. Table I describes the distribution of baseline covariates by exposure groups. The Kaplan-Meier estimators of the 2 survival curves indicate a statistically significant reduction in subsequent AK risk for 5-FU compared to Imq at 2 years but not at 5 years (Fig 2) . The crude (unweighted) estimate of the cumulative risk difference was -4.78% (P = .006) at 2 years and -1.11% (P = .27) at 5 years, whereas the adjusted estimate based on IPW estimation was -4.54% (95% CI, -7.91% to -1.17%) at 2 years and -1.43% (95% CI, -3.43% to 0.05%) at 5 years. The opposite values of these risk differences can be interpreted as the excess risks for subsequent AK if all patients in the cohort were treated with Imq versus if all patients were treated with 5-FU. The hazard ratio from the Cox proportional hazard model fitted with IP weights was 0.929 (95% CI, 0.851-1.015), whereas that fitted without IP weights was 0.945 (95% CI, 0.866-1.032). The maximum value for the IP weights was 2.55, suggesting that extreme weighting and strong observed confounding were not present. 16 
DISCUSSION
In this large cohort study based in a real-world HMO setting with comprehensive integrated health care delivery, we have shown that 5-FU may be more effective than Imq in preventing subsequent AKs in the short term, but we did not find statistically significant evidence of a difference in the long term.
To our knowledge, this is the first study to compare the effectiveness of 5-FU and Imq in preventing subsequent AKs in a real-world setting. Only 2 small randomized trials have directly compared the efficacy of 5-FU and Imq for the treatment of AKs: 1 trial (n = 36; duration, 24 weeks) found that 5-FU was more effective than Imq in reducing final AK count and achieving complete AK clearance, 18 whereas the other (n = 50; duration, 12 months) found that Imq resulted in superior sustained clearance compared with 5-FU. 15 Previous studies have shown that both 5-FU and Imq provide a sustained clinical benefit at 2 years. 12, 19 Our direct comparison of 5-FU and Imq in a real-world clinical setting suggests that 5-FU may be superior to Imq in the short term, though there are no statistically significant long-term differences. Our results are in agreement with a recent meta-analysis that ranked 5-FU higher than Imq in determining the relative efficacy of 8 AK treatments on the basis of complete clearance, 20 leading the authors to conclude that 5-FU should be the treatment of choice for AKs to prevent progression to KC.
The observed differences in duration of effect may be related to the distinct mechanisms of action of 5-FU and Imq. 5-FU decreases cellular proliferation and induces cell death by interfering with DNA and RNA synthesis through inhibition of thymidylate synthetase. 5 In contrast, Imq acts as an immune modulator through the activation of Toll-like receptors, which ultimately induces the production of cytokines and enhances innate and acquire immune responses with antitumor activity. 5 The immune response that Imq induces may be more short-lived than the inhibitory effect of 5-FU on DNA and RNA synthesis. A randomized placebo-controlled trial evaluating the long-term efficacy of 5-FU for AK treatment in 954 patients found that a single course of 5-FU reduced AK counts and the need for spot treatments for longer than 2 years, 12 providing further support for its efficacy at 2 years after treatment.
Strengths of this study include the closed KPNC health care system, which enables a community-based comparison of the efficacy of 5-FU and Imq. The comprehensive care patients receive at KPNC is captured by a computerized health record, allowing us to accurately assess AKs and potential pretreatment confounders. Unlike a clinical trial, this study included patients with a variety of characteristics, not just those who fit specific eligibility criteria. Limitations of this retrospective study include the inability to control for disease severity and the potential for unmeasured pretreatment variables that affect subsequent AK risk and may have been associated with differential prescribing of 5-FU and Imq, such as prior treatment failure. However, we maximized uniformity in the cohort and minimized confounding by unmeasured risk factors by limiting eligibility to members who had sufficient sun damage to have had an AK diagnosed and a topical field-based treatment prescribed. A formal causal analytic approach was used to adjust effect estimates for the potential confounding bias by measured pretreatment covariates, such as prior KC, which may suggest higher disease severity. Prior 5-FU exposure may have affected patients' overall AK burden and influenced subsequent treatment selection given familiarity with the drug, its efficacy, and its side effect profile. Given the potential impact of prior 5-FU exposure on treatment selection and subsequent AK risk, we adjusted for it in our multivariate analysis. Although our analyses did not account for potential bias from differential clinical monitoring during follow-up between the 2 exposure groups (informative interval censoring), differential surveillance is not expected. 15 We relied on prescriptions filled at KPNC pharmacies as a surrogate for medication use, which may not reflect patients' true exposure. However, this reflects a true practice setting and enables measurement of effectiveness, rather than efficacy as in a clinical trial. Treatment with 5-FU and Imq spans several weeks, leading to many opportunities for noncompliance. However, differential noncompliance between the 2 agents was not expected because their directions for use, duration of application, and side effect profiles are quite similar, 15 though a recent Cochrane review did suggest that 5-FU may cause higher rates of irritation than Imq. 5 However, if irritation were to cause decreased compliance among those treated with 5-FU, we would expect to see decreased efficacy in preventing subsequent AKs. We saw a lower risk for AKs among those treated with 5-FU at 2 years, and we might expect to see an even stronger effect were irritation not a confounder. We did not examine subsequent treatment with additional field-based therapies during the study period. Although we did not account for potential informative interval-censoring, we adjusted for differential surveillance before baseline. We ascertained subsequent AK diagnoses through ICD-9 codes, which are not site specific; we were therefore unable to confirm whether subsequent AKs arose in the treated field. However, it is unlikely that there are differential effects on subsequent AKs arising outside the treated field by exposure category (ie, that patients treated with Imq would have fewer or more AKs arising outside the treated area than would patients treated with 5-FU). Finally, our study was conducted among insured adults in northern California. Our results may not be completely generalizable to uninsured persons and other health care or geographic settings.
In summary, our findings suggest that between 5-FU and Imq, which are the 2 most common topical agents for field-based treatment of AKs, 5-FU may be more effective in preventing subsequent AKs in the short term. We found no statistically significant differences in the long term. Though there is still no agreement on the most efficacious AK treatment, 
